First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples